Learning Objectives
- Understand protein engineering and how AI accelerates it
- Understand why Cradle is a rare pure-product play in drug discovery
- Evaluate AI-designed proteins as validated hypotheses
What Is Cradle?
Cradle is an AI protein-engineering company whose product is unusually concrete for the drug-discovery world: software, sold as a subscription, that lets scientists design better proteins in a web browser. Protein engineering — improving a protein's stability, activity, or how well it can be manufactured — normally proceeds through slow rounds of design, laboratory testing, and redesign. A researcher using Cradle specifies the properties they want, and its generative models propose sequence changes to get there, tightening that design-build-test loop so teams reach a good candidate in fewer, smarter iterations.
This makes Cradle one of the clearest AI-vendor products in the field — a sold tool that a scientist uses, not a therapeutics pipeline the company runs itself. Backed by IVP and others, it reports use by several of the world's top-25 pharma companies (including Johnson & Johnson, AbbVie, and Novo Nordisk) across dozens of R&D programs. The honest framing is important: Cradle's designs are hypotheses to validate in the lab, not finished molecules — the model proposes far better candidates to test than trial-and-error alone, and the experimental work still decides what advances. As a browser-based tool, it sits alongside peers like Chai Discovery and Latent Labs in making advanced protein design accessible to working scientists.
💡Key Concept
Design-build-test loop: Protein engineering iterates between designing a variant, testing it in the lab, and redesigning. Cradle's generative models make each design round smarter, so teams reach a strong candidate in fewer cycles.
📝Note
A sold product, not a pipeline: Unlike AI-native biotechs that run their own drug programs, Cradle sells software that other companies' scientists use — one of the clearest AI-vendor products in drug discovery.
✅Tip
Visit Cradle: cradle.bio — subscription software for biotech and pharma R&D teams.
Pricing
Cradle is sold as subscription software to R&D teams rather than fully public list pricing; scope typically depends on seats, programs, and support.
- Browser-based protein design
- Generative sequence proposals
- Design-build-test workflow
- Multi-program deployment
- Support and integration
- Security controls
Core Features
Browser-Based Protein Design
Lets scientists design proteins in a web app, specifying target properties and getting model-proposed sequence changes.
Generative Sequence Models
Uses generative models to propose variants likely to improve stability, activity, or expression.
Tighter Iteration Loop
Aims to reach a strong candidate in fewer design-build-test cycles, saving time and laboratory cost.
Enterprise Adoption
Used by several top-25 pharma companies across dozens of R&D programs, reflecting real-world traction.
Strengths
- A clear, sold product — software scientists use, not a pipeline
- Accessible — advanced protein design in the browser
- Fewer, smarter iterations — tightens the design-build-test loop
- Strong customer base — several top-25 pharma companies
- Peer to accessible design tools — alongside Chai and Latent Labs
Limitations and Considerations
- Designs are hypotheses — laboratory validation still decides
- Domain expertise required — best used by protein scientists
- Scope is protein engineering — not a full discovery pipeline
- Data and target dependence — value varies by problem
- Integration into workflows — fits existing lab processes
Best Use Cases
| Use Case | Why Cradle Fits | Caveat |
|---|---|---|
| Improving protein properties | Generative design in the browser | Validate designs in the lab |
| Speeding the design loop | Fewer, smarter iterations | Domain expertise required |
| Enzyme and antibody engineering | Sequence proposals toward targets | Scope is protein engineering |
| Pharma and biotech R&D | Adopted across many programs | Fits into existing workflows |
Key Takeaways
- Cradle is AI protein-engineering software that lets scientists design better proteins in the browser
- It is one of the clearest AI-vendor products in drug discovery — sold software, not a therapeutics pipeline
- Generative models propose sequence changes toward target properties, tightening the design-build-test loop
- It reports use by several top-25 pharma companies across dozens of programs
- Its designs are hypotheses that require laboratory validation; the model proposes better candidates to test, and experiments decide